The HIPK2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the HIPK2 gene in the HeLa host background. This product provides a heterogeneous pool of edited cells, enabling loss-of-function studies of HIPK2 without clonal selection. The polyclonal format preserves population-level representation of the knockout phenotype, suitable for functional genomics, signaling pathway interrogation, and drug target validation experiments where a mixed genetic background better models biological complexity.
HeLa cells are an immortalized human cervical adenocarcinoma line, originally derived from a cervical carcinoma, and represent a widely used epithelial tumor model in biomedical research. They exhibit robust growth, ease of transfection, and well-characterized responses to genotoxic and cytokine stimuli. This HeLa background provides a relevant cellular context for investigating tumor cell biology, particularly in pathways frequently dysregulated in cervical and other epithelial cancers, including those involving HIPK2.
HIPK2 (homeodomain-interacting protein kinase 2) is a serine/threonine kinase that functions as a transcriptional co-repressor or co-activator, critically regulating apoptosis, cell proliferation, and the DNA damage response. HIPK2 is activated by upstream stress signals including TGF-beta and DNA damage mediated by ATM/ATR kinases. Upon activation, it phosphorylates key downstream targets such as p53, CtBP, c-Jun, and Smad3, modulating their transcriptional activities. HIPK2 interacts with p53, CtBP, Axin, and PML nuclear bodies, and is embedded in signaling networks including p53/Bax/p21-mediated apoptosis, TGF-beta/Smad2/3 transcriptional programs, and Wnt/beta-catenin/GSK-3beta pathways. Through these interactions, HIPK2 integrates genotoxic and cytokine signals to activate cell-cycle arrest or programmed cell death, serving as a central node in tumor suppression.
In the HeLa cervical carcinoma model, disruption of HIPK2 is particularly significant because this cell line harbors wild-type p53 that is efficiently targeted by HIPK2, yet its tumorigenic properties are sustained in part by viral oncoproteins. Loss of HIPK2 function can alter p53-dependent and -independent apoptosis, DNA repair efficiency, and TGF-beta-mediated growth inhibition, offering insights into mechanisms of oncogenesis and therapeutic resistance. This knockout model thus enables dissection of HIPK2’s tumor-suppressive roles in an epithelial context, facilitating studies of signal integration between stress pathways.
This polyclonal HIPK2 knockout product is well-suited for a variety of research applications, including cancer biology investigations, apoptosis profiling, DNA damage signaling analyses, and TGF-beta pathway studies. Representative assays include western blotting, immunofluorescence, TUNEL and caspase activation assays, p53 or TGF-beta-responsive luciferase reporter assays, cell viability and drug sensitivity screens, co-immunoprecipitation, and RT-qPCR. For additional information, technical support, or customization options, please contact Ascent Research.
